Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zars Pharma has reported that Rapydan, a topical local anesthetic patch, has received marketing authorization in Sweden, the UK, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal.
Subscribe to our email newsletter
Zars Pharma has licensed the European sales and marketing rights of Rapydan (70mg lidocaine/70mg tetracaine medicated plaster) to Eusa Pharma. Eusa Pharma began launching Rapydan in other EU countries in early 2008.
Robert Lippert, president and CEO of Zars Pharma, said: “We are pleased to announce the approval of Rapydan in a number of European Union countries with a uniquely positioned commercial partner. Rapydan is the first anesthetic patch innovation to be approved in over a decade that works faster than the current standard of care and will soon become a best-in-class therapy for patients undergoing painful needle procedures.”